Last reviewed · How we verify
NCT04024371: RTOC
Validating Reward-related Biomarkers (RTOC)
trial testing Self-rating Questionnaires in Schizophrenia in 160 participants. Completed in 1 February 2021.
1 February 2021
Quick facts
| Lead sponsor | Maastricht University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 160 |
| Start date | 16 September 2019 |
| Primary completion | 1 February 2021 |
| Estimated completion | 1 February 2021 |
| Sites | 4 locations across Netherlands, Greece, Germany, Spain |
Drugs / interventions tested
- Self-rating Questionnaires
- Measures of Reward processing/reinforcement learning
- Additional Schizophrenia-specific Questionnaires and Interviews
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Depression — all drugs for Depression →
- Motivation — all drugs for Motivation →
- Anhedonia, Physical — all drugs for Anhedonia, Physical →
Sponsor
Maastricht University
Who can join
Adults 20 to 55, any sex, with Schizophrenia or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Deficits or abnormalities in reward processing are present in a number of psychiatric disorders. The overarching objective of the study is to conduct initial validation work towards optimising three experimental tasks - which have previously been shown to be sensitive to reward processing deficits - for future use in clinical trials. This initial validation work has the primary objective to uncover group differences in task outcome measures between healthy control participants, participants with Major Depressive Disorder (MDD) and participants with schizophrenia (SZ) using statistical analyses. This may provide some indications for the use of these tasks as clinically-relevant biomarkers. Primary aims include: (i) comparing the investigator's endpoint means and distributions to those in previously published data; (ii) replication of previously-reported differences between MDD/SZ vs. healthy control participants, and, (iii) exploring the relationship between task endpoints and subjective participant- and clinician-rated report of reward-related constructs (e.g. anhedonia, negative symptoms).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Optimizing Behavioral Paradigms to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder: Study Protocol.
Bilderbeck AC, Raslescu A, Hernaus D, Hayen A, et al · · 2020 · cited 6× · PMID 33250788 · DOI 10.3389/fpsyt.2020.536112
Verify or expand the search:
- PubMed search for NCT04024371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Maastricht University trials
Trials by the same sponsor.
- NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
- NCT07259005 — Breathe Hard to Breathe Easy: Online Breathwork-Assisted Therapy for Social Anxiety · NA · recruiting
- NCT06914648 — The Dragon PLC Trial (DRAGON-PLC) · NA · recruiting
- NCT07374926 — The Big Unknown: A Journey Into Generative AI's Transformative Effect on Medical Professions · NA · completed
- NCT06031818 — Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Pred · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04024371 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maastricht University
- Last refreshed: 26 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04024371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing